Compare Braze Inc (BRZE) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

Braze (BRZE) trades at $26.60, up 5.85% with strong bullish momentum. The stock shows robust revenue growth, increasing from $238M in 2022 to $593M in 2025, though profitability remains negative with a -15.51% net margin. Technical indicators show bullish moving averages but overbought RSI levels. Recent news highlights Goldman Sachs initiation and strong Q1 2027 results with accelerating revenue growth and AI-driven customer engagement tools.

Outlook remains positive with 96% analyst buy ratings and $34.78 consensus target, representing 31% upside. Key risks include persistent losses despite revenue growth and competitive pressures in customer engagement software. The company's AI capabilities and fourth straight quarter of organic revenue acceleration provide growth catalysts, but investors should monitor profitability improvements.

Dentsply Sirona (XRAY) trades at $12.78, up 4.24% today, with technical indicators showing bullish momentum despite recent earnings misses. The company faces fundamental challenges with negative net income margins (-17.06%) and declining revenue trends, though it maintains a solid gross margin of 48.93%. Recent developments include new CFO appointment and expanded distribution partnerships, while analyst consensus remains mixed with a $13.33 price target.

The stock presents a turnaround opportunity with improving cash flow trends and strategic initiatives, but faces significant execution risks amid persistent profitability challenges. Near-term catalysts include Q2 2026 earnings and continued progress on the Return-to-Growth plan, though high debt levels and competitive pressures warrant caution for investors.